Rising Biosciences (Rising Biosciences) Liabilities-to-Assets : 0.00 (As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Rising Biosciences's Total Liabilities for the quarter that ended in . 20 was $0.00 Mil. Rising Biosciences's Total Assets for the quarter that ended in . 20 was $0.00 Mil.

Rising Biosciences Liabilities-to-Assets Historical Data

The historical data trend for Rising Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Liabilities-to-Assets Chart

Rising Biosciences Annual Data

Trend

Liabilities-to-Assets

Rising Biosciences Quarterly Data

Liabilities-to-Assets

Competitive Comparison of Rising Biosciences's Liabilities-to-Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Rising Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rising Biosciences's Liabilities-to-Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rising Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Rising Biosciences's Liabilities-to-Assets falls into.

Rising Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Rising Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in . 20 is calculated as:

Liabilities-to-Assets (A: . 20 )	=	Total Liabilities	/	Total Assets
	=		/
	=	N/A

Rising Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in . 20 is calculated as

Liabilities-to-Assets (Q: . 20 )	=	Total Liabilities	/	Total Assets
	=		/
	=	N/A

Rising Biosciences (GREY:RBII) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Rising Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Rising Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Liabilities-to-Assets

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.